Glanzmann's thrombasthenia future or investigational therapies: Difference between revisions
Gerald Chi- (talk | contribs) mNo edit summary |
m Bot: Removing from Primary care |
||
| (One intermediate revision by one other user not shown) | |||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Gene therapy is a cutting the edge method for treatment of various diseases. Gene therapy in animal models demonstrates good potential of this treatment for curing patients with Glanzmann’s thrombasthenia. As an example for targeting transgene expression in the developing megakaryocytes from two patients with GT in vitro, αIIbβ3 promoter was expressed on these transduced megakaryocytes. CD34+ cells was demonstrated utilizing mice leukemia retrovirus vectors, by this method the Glanzmann’s thrombasthenia was corrected.<ref name="pmid24979837">{{cite journal| author=Blickstein D, Dardik R, Rosenthal E, Lahav J, Molad Y, Inbal A| title=Acquired thrombasthenia due to inhibitory effect of glycoprotein IIbIIIa autoantibodies. | journal=Isr Med Assoc J | year= 2014 | volume= 16 | issue= 5 | pages= 307-10 | pmid=24979837 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24979837 }}</ref> | |||
==Future or Investigational | ==Future or Investigational Therapy== | ||
Gene therapy has a significant potential for curing Glanzmann’s thrombasthenia in the near future.<ref name="pmid26185478">{{cite journal| author=Solh T, Botsford A, Solh M| title=Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. | journal=J Blood Med | year= 2015 | volume= 6 | issue= | pages= 219-27 | pmid=26185478 | doi=10.2147/JBM.S71319 | pmc=4501245 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26185478 }}</ref> | |||
==References== | ==References== | ||
| Line 13: | Line 15: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
Latest revision as of 21:52, 29 July 2020
|
Glanzmann's thrombasthenia |
|
Differentiating Glanzmann's thrombasthenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glanzmann's thrombasthenia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Glanzmann's thrombasthenia future or investigational therapies |
|
FDA on Glanzmann's thrombasthenia future or investigational therapies |
|
CDC on Glanzmann's thrombasthenia future or investigational therapies |
|
Glanzmann's thrombasthenia future or investigational therapies in the news |
|
Blogs on Glanzmann's thrombasthenia future or investigational therapies |
|
Risk calculators and risk factors for Glanzmann's thrombasthenia future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Gene therapy is a cutting the edge method for treatment of various diseases. Gene therapy in animal models demonstrates good potential of this treatment for curing patients with Glanzmann’s thrombasthenia. As an example for targeting transgene expression in the developing megakaryocytes from two patients with GT in vitro, αIIbβ3 promoter was expressed on these transduced megakaryocytes. CD34+ cells was demonstrated utilizing mice leukemia retrovirus vectors, by this method the Glanzmann’s thrombasthenia was corrected.[1]
Future or Investigational Therapy
Gene therapy has a significant potential for curing Glanzmann’s thrombasthenia in the near future.[2]
References
- ↑ Blickstein D, Dardik R, Rosenthal E, Lahav J, Molad Y, Inbal A (2014). "Acquired thrombasthenia due to inhibitory effect of glycoprotein IIbIIIa autoantibodies". Isr Med Assoc J. 16 (5): 307–10. PMID 24979837.
- ↑ Solh T, Botsford A, Solh M (2015). "Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options". J Blood Med. 6: 219–27. doi:10.2147/JBM.S71319. PMC 4501245. PMID 26185478.